Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabe...

Full description

Bibliographic Details
Main Authors:	Kahn, SE, Haffner, S, Heise, M, Herman, W, Holman, R, Jones, N, Kravitz, BG, Lachin, J, O'Neill, M, Zinman, B, Viberti, G
Format:	Journal article
Language:	English
Published:	2006

Similar Items

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
by: Lachin, J, et al.
Published: (2011)

Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain
by: Haffner, S, et al.
Published: (2007)

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
by: Kahn, SE, et al.
Published: (2011)

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
by: Zinman, B, et al.
Published: (2010)

ADOPT: The effectiveness of metformin versus glyburide in type 2 diabetes
by: Herman, W, et al.
Published: (2007)

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
by: Kahn, SE, et al.
Published: (2010)

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
by: Viberti, G, et al.
Published: (2002)

A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes
by: Viberti, G, et al.
Published: (2002)

Determinants of monotherapy failure in ADOPT - (A diabetes outcome progression trial)
by: Holman, R, et al.
Published: (2007)

Rosiglitazone-associated fractures in type 2 diabetes
by: Kahn, SE, et al.
Published: (2008)

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
by: Kahn, SE, et al.
Published: (2008)

Increased incidence of fractures in women who received rosiglitazone in ADOPT (A Diabetes Outcome Progression Trial)
by: Kahn, SE, et al.
Published: (2007)

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.
by: Kahn, SE, et al.
Published: (2006)

Changes in bone metabolism biomarkers in the ADOPT study
by: Kahn, SE, et al.
Published: (2008)

Quantifying the effect of metformin treatment and dose on glycemic control.
by: Hirst, J, et al.
Published: (2012)

Incidence of diabetes following ramipril or rosiglitazone withdrawal
by: Holman, R, et al.
Published: (2011)

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.
by: Cook, M, et al.
Published: (2005)

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
by: Ferrannini, E, et al.
Published: (2009)

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
by: Ahrén, B, et al.
Published: (2010)

Prevalence of microalbuminuria in recently diagnosed Type 2 diabetes mellitus and its relationship to non-traditional risk factors: observations from the ADOPT study
by: Viberti, G, et al.
Published: (2003)

Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
by: Agbaje, O, et al.
Published: (2017)

Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.
by: Wright, A, et al.
Published: (2006)

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.
by: Zhou, K, et al.
Published: (2011)

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
by: Zhou, K, et al.
Published: (2011)

Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis.
by: Koh, G, et al.
Published: (2011)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49)
by: Turner, R, et al.
Published: (1999)

Liraglutide add-on to metformin improves postprandial glucose control compared with metformin monotherapy in patients with Type 2 diabetes: posthoc analysis of the Liraglutide Effect and Action in Diabetes (LEAD)2 study
by: Stephens, J, et al.
Published: (2014)

Metformin and risk of cardiovascular disease.
by: Turner, R, et al.
Published: (1999)

Rosiglitazone reduces hepatic fat content
by: Buckingham, R, et al.
Published: (2000)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
by: Turner, R, et al.
Published: (1999)

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
by: Charbonnel, B, et al.
Published: (2005)

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
by: Gerstein, H, et al.
Published: (2006)

Guidance on rosiglitazone for type 2 diabetes mellitus.
by: Matthews, DR
Published: (2001)

Incidence of diabetes following ramipril or rosiglitazone withdrawal.
by: Investigators, D
Published: (2011)

METFORMIN IN THE MANAGEMENT OF TYPE-2 DIABETES - REPLY
by: Holman, R, et al.
Published: (1989)

No glycemic benefit from guar administration in NIDDM.
by: Holman, R, et al.
Published: (1987)

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
by: Hanefeld, M, et al.
Published: (2004)

Metformin and mortality. Reply to Lund SS [letter]
by: Stevens, R, et al.
Published: (2013)

Metformin and mortality. Reply to Lund SS [letter].
by: Stevens, R, et al.
Published: (2013)

Metformin as first choice in oral diabetes treatment: the UKPDS experience.
by: Holman, R
Published: (2007)